Zacks Research Has Positive Estimate for WST Q4 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) - Equities researchers at Zacks Research increased their Q4 2025 EPS estimates for West Pharmaceutical Services in a research report issued to clients and investors on Wednesday, April 9th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of $1.86 for the quarter, up from their prior estimate of $1.85. The consensus estimate for West Pharmaceutical Services' current full-year earnings is $6.62 per share.

Several other equities research analysts have also issued reports on the stock. Evercore ISI began coverage on shares of West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an "outperform" rating and a $275.00 target price for the company. Citigroup assumed coverage on shares of West Pharmaceutical Services in a research report on Wednesday, January 8th. They issued a "buy" rating and a $400.00 target price for the company. KeyCorp dropped their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. StockNews.com lowered West Pharmaceutical Services from a "buy" rating to a "hold" rating in a research report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 target price for the company in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $332.50.

Remove Ads

West Pharmaceutical Services Price Performance

Shares of WST traded down $3.22 during trading hours on Monday, reaching $209.28. 954,836 shares of the company's stock traded hands, compared to its average volume of 692,793. The company has a current ratio of 2.79, a quick ratio of 2.23 and a debt-to-equity ratio of 0.08. The firm's 50 day simple moving average is $226.99 and its 200-day simple moving average is $288.51. The stock has a market cap of $15.13 billion, a PE ratio of 31.28, a price-to-earnings-growth ratio of 6.74 and a beta of 1.22. West Pharmaceutical Services has a 12 month low of $187.43 and a 12 month high of $394.42.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The firm had revenue of $748.80 million during the quarter, compared to analyst estimates of $739.59 million.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 7th. Stockholders of record on Wednesday, April 30th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Wednesday, April 30th. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 12.56%.

Hedge Funds Weigh In On West Pharmaceutical Services

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fiera Capital Corp boosted its stake in shares of West Pharmaceutical Services by 13.2% during the fourth quarter. Fiera Capital Corp now owns 140,893 shares of the medical instruments supplier's stock valued at $46,151,000 after purchasing an additional 16,418 shares during the period. Trust Point Inc. boosted its position in West Pharmaceutical Services by 321.0% during the 4th quarter. Trust Point Inc. now owns 3,183 shares of the medical instruments supplier's stock valued at $1,043,000 after buying an additional 2,427 shares during the period. Savant Capital LLC boosted its position in West Pharmaceutical Services by 15.0% during the 4th quarter. Savant Capital LLC now owns 1,003 shares of the medical instruments supplier's stock valued at $329,000 after buying an additional 131 shares during the period. Sanctuary Advisors LLC grew its holdings in West Pharmaceutical Services by 80.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 6,800 shares of the medical instruments supplier's stock worth $2,153,000 after acquiring an additional 3,042 shares during the last quarter. Finally, Avanza Fonder AB purchased a new position in shares of West Pharmaceutical Services in the fourth quarter valued at about $2,553,000. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.